Adenocarcinoma Of The Prostate clinical trials

Explore recruiting adenocarcinoma of the prostate clinical trials.

Recruiting adenocarcinoma of the prostate studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Adenocarcinoma Of The Prostate trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

PEACE 6 Vulnerable : A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents.

France, Spain, Ireland, Belgium, Italy, Romania +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01).

Belgium, Netherlands, Germany, Sweden, Finland, Poland +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate Cancer

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate Prostate01)

Norway, Sweden, Greece, Germany, France, Spain +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy

Austria, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Adenocarcinoma Of The Prostate trials by city

Adenocarcinoma Of The Prostate in Toronto Adenocarcinoma Of The Prostate in Vancouver Adenocarcinoma Of The Prostate in Montreal Adenocarcinoma Of The Prostate in Calgary Adenocarcinoma Of The Prostate in Edmonton Adenocarcinoma Of The Prostate in Ottawa Adenocarcinoma Of The Prostate in Winnipeg Adenocarcinoma Of The Prostate in Quebec City Adenocarcinoma Of The Prostate in Hamilton Adenocarcinoma Of The Prostate in Kitchener Adenocarcinoma Of The Prostate in London Adenocarcinoma Of The Prostate in Halifax Adenocarcinoma Of The Prostate in New York Adenocarcinoma Of The Prostate in Los Angeles Adenocarcinoma Of The Prostate in Chicago Adenocarcinoma Of The Prostate in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease